Savara Inc.

NASDAQ:SVRA

Biotechnology

Healthcare
$4.72 +0.46%

+$0.03 today

Market cap
$1.04B
Beta
0.27
P/E (TTM)
-10.6
EPS (TTM)
-$0.51
52W Low $1.98High $7.01

Volume 5.51M

Average 1.53M

SVRA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Savara Inc.NASDAQ: SVRA

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $66K fell 92.7% year over year, ahead of the -97.8% change in trailing-twelve-month cost of revenue. Sequentially, it rose 65.0% from the prior quarter. Over 3 fiscal years it compounded at -79.4% a year.

Context

  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -92.7% holds above the trailing-twelve-month pace of -97.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$66K+65.0% QoQ
Last fiscal yearDec 2025
$245K-99.7% YoY
LTMMar 2026
$491K-97.8% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-92.7%——
1 year-99.7%——
3-year CAGR-79.4%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
245K USD
Year-over-year change
-99.7%
4-year CAGR
-69.7%

Cost of Revenue vs competitors

How SVRA compares with its peers on the latest reported figures

  • SVRA's LTM Mar 2026 cost of revenue of $491K is the lowest of the 2 companies compared; the peer median is $21.55M.
  • Its year-over-year change of -97.8% is the lowest of 2, against a peer median of -46.3%.
  • Over three fiscal years its annual growth of -79.4% compares with a peer median of -55.7%.
SVRA Competitors Peer median
Cost of Revenue for SVRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TBPHTheravance Biopharma, Inc.LTM Mar 2026$21.55M -46.3%-55.7%19.6%
SVRASavara Inc.LTM Mar 2026$491K -97.8%-79.4%—
APMDApnimed, Inc.—— ———
Peer median (excluding SVRA) $21.55M-46.3%-55.7%19.6%

Competitors are the stored peer set for SVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue28.99M27.88M44.26M78.03M245K
Gross Profit(28.99M)(27.88M)(44.26M)(78.03M)(245K)
Gross Margin—————
Research & Development28.99M27.88M44.26M78.03M81.4M
Selling, General & Admin12.35M10.93M15.67M25.04M42.06M
Operating Expenses12.49M10.96M15.75M25.17M123.3M
Depreciation & Amortization136K31K77K130K245K
EBITDA(40.5M)(38.01M)(59.13M)(102.27M)(118.59M)
EBITDA Margin—————
Operating Income(41.48M)(38.84M)(60.01M)(103.2M)(123.55M)
Operating Margin—————
Interest Income2.28K884.44M6.47M4.16M
Interest Expense2.28M88K000
Other Income / Expenses(1.54M)689K5.31M7.32M4.71M
Income Before Tax(43.01M)(38.15M)(54.7M)(95.88M)(118.84M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(43.01M)(38.15M)(54.7M)(95.88M)(118.84M)
Net Margin—————
EPS (Basic)(0.32)(0.25)(0.33)(0.48)(0.53)
EPS (Diluted)(0.32)(0.25)(0.33)(0.48)(0.53)
Weighted Avg Shares133.92M152.77M165.2M198.19M222.39M
Weighted Avg Shares (Diluted)133.92M152.77M165.2M198.19M222.39M

Savara Inc.

NASDAQ:SVRA

Intrinsic Alpha fair value

Locked

Current Price

$4.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.